[{"id":"40516fe7-06f1-4482-9d62-ee5ed2208d4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02930993","created_at":"2021-01-18T14:23:37.310Z","updated_at":"2024-07-02T16:37:28.541Z","phase":"Phase 1","brief_title":"Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors","source_id_and_acronym":"NCT02930993","lead_sponsor":"China Meitan General Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • MSLN CAR-T • anti-mesothelin CAR T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2016-10-12"}]